A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals
Source:

3P Biopharmaceuticals

November 28, 2019

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, the UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment.

3P Biopharmaceuticals and In3Bio began their partnership in early 2019 with 3P Biopharmaceuticals being selected to be responsible for technology transfer, process development, analytical methods development, scale-up and cGMP production for clinical studies.

In3Bio’s candidate molecule is IN02, a bi-specific biological molecule that was identified through designing fusions of molecules with high binding potential for targeting growth factors.

The technology employed by In3Bio produces new molecules specific to one or multiple growth factors at the same time. In this way, these new candidates have demonstrated a wide potential in the treatment of different cancer indications using established preclinical models, opening the door for developing effective anti-tumour therapy.

As 3P Biopharmaceuticals CEO Dámaso Molero explains, “it is an honour to help develop an anti-cancer treatment and do our best in the field of oncology with the hope of ultimately contributing to a positive effect on society“. Besides, Molero added, “this innovative project strengthens the experience of 3P Biopharmaceuticals to develop complex therapeutic products applied to health and places us among the most competitive CDMOs in Europe.

Erik D’Hondt, CEO/CSO at In3Bio, added: “We at IN3BIO are pleased to cooperate with 3P Biopharmaceuticals, a CDMO with solid and broad experience to support IN3BIO for preparing Clinical batch of a chimeric biological molecule to be used in the clinic”.

According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide and was responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer.

Therefore, this development represents an important advance for oncological treatments, which are critically needed given the increasing rates in cancer.

Through this collaboration, 3P Biopharmaceuticals once again demonstrates its capacity to carry out processes and manufacturing for molecules developed within diverse therapeutic applications.

About 3P Biopharmaceuticals

3P Biopharmaceuticals is a leading CDMO specialized in process development and GMP manufacturing of biologics and cell therapy products. 3P offers solutions at all stages of biologics development, from initial process and analytics development to preclinical and clinical phases and commercial production. Its extensive experience, flexibility, and adaptation, as well as its innovative technology and qualified team, have made 3P an example for the international market.

Further information: http://www.3pbio.com/

About In3Bio

In3Bio is a UK based Biotech company that develops a novel approach in oncology, perhaps the best tolerability profile used in oncology.

In3Bio obtained the patent on a technological platform of new biological molecules for use in the treatment of solid cancers. In3Bio is currently conducting a Phase I clinical trial in centers in Spain with a combination of EGFR TKI and EGF vaccine. The company has tested small molecule inhibitors in suitable cell lines and has demonstrated that the efficacy of the 15 small molecules tested has benefited significantly from the combination with IN01, one of the patented molecules developed by In3Bio.

The company is currently ready to start several phases I clinical trials in 2020 and is developing the preparation of the clinical batch of IN02, another In3Bio molecule.

Further information: http://in3bio.com/

Posted in: Biotechnology, Cancer

Post a Comment

You must be logged in to post a Comment.

FEEDBACK